A Study of Efficacy, Safety, and Tolerability of KAN-101 in People with Celiac Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

January 3, 2025

Study Completion Date

January 13, 2025

Conditions
Celiac DiseaseCoeliac Disease
Interventions
DRUG

KAN-101

Dose KAN-101 Intravenous (IV) Infusion

DRUG

Placebo

Placebo Intravenous (IV) Infusion

Trial Locations (28)

6108

Studiengesellschaft BSF Unternehmergesellschaft, Halle

20520

Clinical Research Services Turku, Turku

33018

Unlimited Medical Research Group, Hialeah Gardens

33032

Homestead Associates in Research Inc., Miami

33520

Tays Research Services, Tampere

67207

Alliance for Multispecialty Research, LLC, Wichita

70121

Ochsner Clinic Foundation, New Orleans

80907

Peak Gastroenterology Associates, Colorado Springs

4941492

Rabin Medical Center, Petah Tikva

5265601

Sheba Medical Center, Ramat Gan

8410101

Soroka Medical Center, Beersheba

9103102

Shaare Zedek Medical Center, Jerusalem

02215

Beth Israel Deaconess Medical Center, Boston

L8S 4L8

McMaster University, Hamilton

N6A 5W9

LHSC, London

G6V 3Z1

Centre Intégré de Santé et de Services Sociaux-Chaudière Appalaches - Hôtel-Dieu de Lévis, Lévis

H4J 1C5

Hopital Du Sacre-Coeur De Montreal, Montreal

G1V 4T3

Diex Recherche Quebec Inc., Québec

00180

CRST Helsinki Oy, Helsinki

D15X40D

Connolly Hospital, Dublin

A92VW28

Our Lady of Lourdes Hospital, Drogheda

N91Na43

Midland Regional Hospital Mullingar, Mullingar

3318AT

Albert Schweitzer Ziekenhuis, locatie Dordwijk, Dordrecht

87-100

Gastromed Sp. z o. o., Torun

50-449

Melita Medical, Wroclaw

00-728

WIP Warsaw IBD Point Profesor Kierkuś, Warsaw

44-190

MZ Badania Slowik Zymla Spolka Jawna, Knurów

91-034

Centrum Medyczne Med-Gastr Sp. z o.o., Lodz

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

INDUSTRY